[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357210-105":59,"doc-detail-357210-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ai-in-prostate-cancer-screening-diagnosis-a-registry-based-study-of-clinicaltrialsgov-trials-registry-based-evidence-mapping-and-trial-landscape-summary","AI in Prostate Cancer Screening & Diagnosis - A Registry-Based Study of ClinicalTrials.gov Trials - Registry-based Evidence Mapping and Trial Landscape Summary","","Artificial intelligence is increasingly used for prostate cancer screening and diagnostic evaluation, yet the structure, methods, and clinical role of AI-focused trials are not fully described. This registry-based evidence-mapping study systematically identified eligible ClinicalTrials.gov studies up to 15 November 2025. Eighty-four trials were included, with imaging-based AI dominating and most studies using prospective observational designs and stand-alone evaluation. Reference standards often relied on histopathology or biopsy confirmation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ai-in-prostate-cancer-screening-diagnosis-a-registry-based-study-of-clinicaltrialsgov-trials-registry-based-evidence-mapping-and-trial-landscape-summary/357210/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ai-in-prostate-cancer-screening-diagnosis-a-registry-based-study-of-clinicaltrialsgov-trials-registry-based-evidence-mapping-and-trial-landscape-summary/357210.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of this registry-based evidence-mapping study?","Question",{"text":112,"@type":113},"To map the clinical trial landscape of AI applications in prostate cancer diagnosis using registry-based evidence.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many trials met the study’s inclusion criteria?",{"text":117,"@type":113},"A total of 84 trials met the inclusion criteria.",{"name":119,"@type":110,"acceptedAnswer":120},"What role and validation strategy did the study suggest for current AI diagnostic research?",{"text":121,"@type":113},"Evidence indicates AI systems are mostly positioned as decision-support tools, with greater emphasis needed on multicenter validation, standardized reporting, and clinically relevant outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},357210,1790472448,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","AI in Prostate Cancer Screening & Diagnosis: A Registry-Based [Study of ClinicalTrials.gov](Study of ClinicalTrials.gov)[ ](Study of ClinicalTrials.gov)Trials  \nINQUIRY: The Journal of Health Care  \nOrganization, Provision, and Financing Volume 63: 1–14 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/00469580261457387](DOI: 10.1177/00469580261457387)  \n[journals.sagepub.com/home/inq](journals.sagepub.com/home/inq)  \nRawan H. Hareeri1 and Mohammed M. Aldurdunji2   \nAbstract  \nIntroduction: Artificial intelligence (AI) is increasingly applied in prostate cancer screening and diagnostic evaluation; however, the structure, methodological characteristics, and clinical positioning of AI-focused trials remain incompletely characterized. This study aimed to map the clinical trial landscape of AI applications in prostate cancer diagnosis using registry-based evidence mapping. Methods: A registry-based evidence-mapping analysis was conducted using [ClinicalTrials.gov. Trials registered up to 15 November 2025 were systematically identified using search terms related to](ClinicalTrials.gov. Trials registered up to 15 November 2025 were systematically identified using search terms related to)[ ](ClinicalTrials.gov. Trials registered up to 15 November 2025 were systematically identified using search terms related to)[prostate cancer and AI-based methodologies](prostate cancer and AI-based methodologies). Eligible studies included interventional and observational trials evaluating AI applications for diagnostic purposes. Data were extracted on study design, diagnostic modality, functional role of AI, comparator framework, and validation strategy. Descriptive statistics and cross-tabulation analyses were used to characterize patterns across studies. The study selection process was presented using a PRISMA-style flow diagram. Results: A total of 84 trials met the inclusion criteria. Imaging-based AI applications predominated, accounting for 52.4% of studies, with magnetic resonance imaging (MRI) representing the most frequently investigated modality (34.5%) . Biomarker-based (16.7%), multimodal (15.5%), and computational pathology (7.1%) approaches were less frequently reported. The most common functional applications were classification and risk prediction (48.8%) and lesion detection and segmentation (29.8%) . Most studies employed prospective observational designs (84.5%) and frequently relied on stand-alone AI evaluation frameworks (39.2%) . Histopathology or biopsy confirmation was the most commonly reported reference standard (56.0%). Only a limited number of trials incorporated workflow integration or clinical decision-support evaluation. Conclusion: AI research in prostate cancer diagnostics appears to be primarily centered on imaging-based, early-phase, and performance-oriented studies. Current evidence suggests that AI systems are predominantly positioned as decision-support tools rather than fully integrated clinical solutions. Greater emphasis on multicenter validation, standardized reporting, and clinically relevant outcome evaluation may be required to support broader clinical implementation.  \nKeywords  \nArtificial intelligence, Prostate cancer, Diagnostic imaging, multiparametric MRI, Digital pathology, Clinical trials  \nReceived: 8 January 2026; Revised: 11 May 2026; Accepted: 18 May 2026  \n1Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia 2Pharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia  \nCorresponding author:  \nMohammed M. Aldurdunji, Pharmaceutical Practices Department, College of Pharmacy, UmmAl-Qura University Makkah, Al Taef road, Makkah 24342, Saudi Arabia.  \n[Email:](Email: mmdurdunji@uqu.edu.sa)[ mmdurdunji@uqu.edu.sa](Email: mmdurdunji@uqu.edu.sa)  \nCreative Commons Non Commercial CC BY-NC: This article is distribute","cbCaibFbFKLwGyPX","https://ap.wps.com/l/cbCaibFbFKLwGyPX","pdf",1724219,14,"English","# Introduction\n## Study aims\n# Methods\n## Evidence mapping approach\n## Eligibility and data extraction\n## Study selection (PRISMA-style)\n# Results\n## Trial counts and distribution by AI modality\n## Functional applications and study designs\n## Reference standards\n## Workflow and decision-support evaluation\n# Conclusion","[{\"question\":\"What was the purpose of this registry-based evidence-mapping study?\",\"answer\":\"To map the clinical trial landscape of AI applications in prostate cancer diagnosis using registry-based evidence.\"},{\"question\":\"How many trials met the study’s inclusion criteria?\",\"answer\":\"A total of 84 trials met the inclusion criteria.\"},{\"question\":\"What role and validation strategy did the study suggest for current AI diagnostic research?\",\"answer\":\"Evidence indicates AI systems are mostly positioned as decision-support tools, with greater emphasis needed on multicenter validation, standardized reporting, and clinically relevant outcomes.\"}]","AI in Prostate Cancer Screening & Diagnosis - A Registry-Based Study of ClinicalTrials.gov Trials - Registry-based Evidence Mapping and Trial Landscape Summary | PDF",1790129351,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2aefea8c634501220f2f0b47e1a8f1ab.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80c1dfb7412b24c70821a4248e3ed77e.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d33df740abcac402d402f9fb364fc284.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e53cab00e6772667e0a6d76bf1225025.webp",980,1306]